Angiogenesis inhibitors such as lenvatinib and sorafenib, and an immune checkpoint inhibitor (ICI), nivolumab, are used for anticancer therapies against advanced hepatocellular carcinoma (HCC). Combination treatments comprising angiogenesis inhibitors plus ICIs are promising options for improving clinical benefits in HCC patients, and clinical trials are ongoing. Here, we investigated the antitumor and immunomodulatory activities of lenvatinib (a multiple receptor tyrosine kinase inhibitor targeting vascular endothelial growth factor receptor 1-3, fibroblast growth factor receptor 1-4, platelet-derived growth factor receptor α, KIT and RET) and the combined antitumor activity of lenvatinib plus anti-programmed cell death 1 (PD-1) antibody in the Hepa1-6 mouse HCC syngeneic model. We found that the antitumor activities of lenvatinib and sorafenib were not different in immunodeficient mice, but lenvatinib showed more potent antitumor activity than sorafenib in immunocompetent mice.
| INTRODUC TI ON
Liver cancer is the second most common cause of death from cancer worldwide, 1 with hepatocellular carcinoma (HCC) accounting for approximately 80% of primary malignant liver cancers. 2 Although the incidence and mortality of HCC are relatively high in Asia and Africa (eg, approximately 50% of the total number of cases and deaths in China), the incidence and mortality of HCC have been increasing in the USA over the past few decades. 3, 4 The multitargeted tyrosine kinase inhibitor sorafenib tosylate (sorafenib), which primarily targets Raf serine/threonine kinases, vascular endothelial growth factor receptor (VEGFR) 1-3, platelet-derived growth factor receptor (PDGFR) α and β, FLT3, RET and KIT, was approved for the treatment of unresectable HCC in 2007. 5 Since then, sorafenib has been used as the only evidence-based systemic treatment option for first-line therapy in patients with advanced HCC. However, its overall outcomes are not fully satisfactory (objective response rate [ORR], 2% 5 ) and there is an unmet medical need to improve anticancer therapy against advanced HCC.
Lenvatinib mesilate (lenvatinib) is an oral multitargeted tyrosine kinase inhibitor with antitumor and antiangiogenic activities via inhibition of VEGFR 1-3, fibroblast growth factor receptor (FGFR) 1-4, PDGFR α, RET and KIT. 6 Preclinical studies have demonstrated that lenvatinib has potent antiangiogenic activity through inhibition of both the VEGF and FGF signaling pathways 7 and shows antitumor activity consistently across diverse solid tumor models such as thyroid cancer, renal cell carcinoma (RCC) and HCC. 6, 8, 9 Lenvatinib is used globally to treat progressive, locally recurrent or metastatic, radioactive iodine-refractory differentiated thyroid cancer, and is used in Japan to treat unresectable thyroid cancer. 10 In addition, the combination treatment of lenvatinib plus everolimus has been approved for metastatic RCC following a previous VEGF-targeted therapy in the USA and the European Union (EU). 11 Recently, lenvatinib showed non-inferiority in overall survival and superiority in progression-free survival, time to progression and ORR when compared with sorafenib as first-line treatment for unresectable HCC in an international multicenter clinical trial. 12 On the basis of the results of this trial, lenvatinib was recently approved for first-line treatment of patients with unresectable HCC in the USA, the EU, China, Japan and other countries.
Recently, agents targeting immune checkpoint signaling have
shown promising results in patients with several malignancies, such as melanoma and non-small cell lung cancer. 13, 14 Such agents may also be an attractive therapeutic option for HCC because an inflammatory tumor microenvironment is associated with improved survival. 15, 16 
| MATERIAL S AND ME THODS

| Cells and reagents
Hepa1-6 cells, derived from the BW7756 tumor in a C57L mouse, were obtained from the ATCC (Manassas, VA, USA). The cells were cultured in high-glucose DMEM (Wako Pure Chemical Industries, Osaka, Japan) supplemented with 10% FBS (Sigma-Aldrich, St. Louis, MO, USA) and 1% penicillin-streptomycin (Wako Pure Chemical Industries) at 37°C under a 5% CO 2 atmosphere.
Lenvatinib was synthesized at Eisai (Ibaraki, Japan). Sorafenib was purchased from Bayer Yakuhin (Osaka, Japan). Anti-mouse PD-1 Ab (anti-PD-1 Ab; clone RMP1-14), anti-mouse CD8α Ab (anti-CD8 Ab;
clone YTS 169.4), and mouse isotype control IgG (control IgG; clone LTF-2) were purchased from Bio X Cell (West Lebanon, NH, USA). 
| In vitro proliferation assay
| CD8 + T cell depletion by anti-mouse
CD8α antibody
Nine days after inoculation of Hepa1-6 cells into C57L/J mice, mice were intraperitoneally injected with either control IgG (200 μg/head) or anti-CD8 Ab (200 μg/head). Three days after control IgG or anti-CD8 Ab injection (day 1), both groups were divided into 3 groups:
non-treatment, lenvatinib treatment, and sorafenib treatment.
Lenvatinib or sorafenib were orally administered once daily. Control
IgG or anti-CD8 Ab was also intraperitoneally injected twice weekly.
| Response evaluation
Tumor volume change at time t (ΔTV) was expressed as a percentage of the baseline value as follows: ΔTV = 100% × ([TVt − TV1]/ TV1). The best response was the minimum value of ΔTV for t ≥ 11 days. For each time t, the average ΔTV from t = 1 to t was also calculated. Response was evaluated based on modified RECIST (Response Evaluation Criteria in Solid Tumors) criteria for mouse studies 20, 21 and defined as follows (applied in this order): complete response (CR), best response <−95%; partial response (PR), best response <−50%; stable disease (SD), best response <35%; progressive disease (PD), not otherwise categorized.
| Flow cytometry analysis and immune cell profiling by viSNE analysis
Tumor tissues resected from mice were dissociated into single cells by using a Tumor Dissociation Kit and a gentleMACS Dissociator (Table S1 ) and DAPI (4′,6-diamidino-2-phenylindole; Dojindo). Cells were analyzed with a LSRFortessa X-20 flow cytometer (BD Biosciences), and then viSNE analysis 22 was conducted with
Cytobank software (Cytobank, Santa Clara, CA, USA).
| Single-cell analysis
After tumor dissociation and isolation of CD45 + cells as described for FCM analysis, isolated cells were pooled in equal numbers 
| Statistical analyses
Experiment data were expressed as means + SEM; n is the number of independent experiments conducted. tumor is a T cell-inflamed tumor.
To investigate the antitumor activities of lenvatinib and sorafenib, we first examined the cell growth inhibitory activities of both drugs against Hepa1-6 cells in an in vitro proliferation assay and confirmed that neither has potent direct cell growth inhibitory activities: IC 50 values of lenvatinib and sorafenib were >30 and 9.7 μmol/L, respectively ( Figure S1 ), which are not clinically meaningful concentrations. 25, 26 We next assessed the antitumor activities These results show that lenvatinib has immunomodulatory activity that enhances antitumor activity under the immunocompetent tumor microenvironment in the Hepa1-6 syngeneic mouse model. 
| Attenuation
| D ISCUSS I ON
In this study, we used the Hepa1-6 tumor model in C57L/J mice as an HCC syngeneic model 22, 23 to investigate the role of the immunomodulatory activity of lenvatinib in its antitumor activity.
FCM analysis followed by viSNE analysis revealed that the CD8 + T cell population accounted for approximately 30% of CD45 + TILs in Hepa1-6 tumor tissues, and many CD8 + T cells expressed immune checkpoint receptors such as PD-1 and TIM-3. Because CD8 + T cells with dual expression of PD-1 and TIM-3 are known to exhibit the most severe exhausted phenotype, 27 our results indicate that the CD8 + T cells in the Hepa1-6 tumor tissues had already been activated more than once by neo-antigens derived from Hepa1-6 tumor tissues before drug treatment. This immune active phenotype of the Hepa1-6 tumor model was consistent with the significant increase in tumor growth rate observed in the CD8 + T cell-depleted condition. Based on these data, we consider that the Hepa1-6 syngeneic mouse tumor model is a T cell-inflamed HCC preclinical model that can be used to examine the immunomodulatory effect of lenvatinib on antitumor immunity. In fact, the inflamed tumor phenotype likely exists as the minority of HCC. 28 We previously observed that lenvatinib modulates the cancer immunity associated with a decrease in tumor-associated macrophages and an increase in interferon-gamma production in CD8 
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